Pretreatment serum monocyte chemoattractant protein‐1 as a predictor of long‐term outcome by ustekinumab in patients with Crohn's disease
- 8 March 2023
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 38 (6), 910-920
- https://doi.org/10.1111/jgh.16151
Abstract
Background and AimsUstekinumab has been proven to be effective for treatment of patients with Crohn's disease; however, 30-40% of patients have been reported to lose clinical response within 2 years. We aimed to evaluate the efficacy of ustekinumab and identify predictors of short-term and long-term efficacy in Crohn's disease. MethodsPatients with Crohn's disease receiving their first ustekinumab infusion in our hospital between June 2017 and September 2020 were prospectively enrolled. Concentrations of serum cytokines and chemokines were measured using a multiplex bead array assay. ResultsFifty-nine Crohn's disease patients were enrolled in this study. Among 34 clinically active patients, 38.2% achieved a clinical response at week 8. None of the assayed factors were associated with short-term clinical response. Cumulative persistence rates of ustekinumab were 77.6% at 1 year and 58.9% at 2 years. Univariate Cox regression analysis revealed that Harvey-Bradshaw Index scores at baseline, concomitant immunomodulator treatment, and concentrations of interferon gamma-induced protein-10, monocyte chemoattractant protein-1 (MCP-1), and interleukin (IL)-1RA, IL-4, IL-6, and IL-8 were significantly associated with loss of efficacy. Multivariate Cox regression analysis found that biologic naive status (hazard ratio [HR]: 0.1191, 95% confidence interval [CI]: 0.02458-0.5774) and MCP-1 concentrations (HR: 1.038, 95% CI: 1.015-1.062) were significantly and associated with loss of sustained efficacy for ustekinumab treatment. ConclusionsOur findings suggest that pretreatment serum MCP-1 analysis, combined with a history of biologic use, could be a novel biomarker for predicting the long-term efficacy of ustekinumab in patients with Crohn's disease.Keywords
Funding Information
- Japan Society for the Promotion of Science (19K17472)
This publication has 42 references indexed in Scilit:
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Discovery and mechanism of ustekinumabmAbs, 2011
- Pathogenesis of postoperative recurrence in Crohn's diseaseGut, 2010
- Monocyte Chemoattractant Protein-1 (MCP-1): An OverviewJournal of Interferon & Cytokine Research, 2009
- Critical role of MCP-1 in the pathogenesis of experimental colitis in the context of immune and enterochromaffin cellsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2006
- The Montreal classification of inflammatory bowel disease: controversies, consensus, and implicationsGut, 2006
- Induction of a fibrogenic response in mouse colon by overexpression of monocyte chemoattractant protein 1Gut, 2006
- A distinct subset of chemokines dominates the mucosal chemokine response in inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2004
- Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's diseaseThe Journal of Pathology, 2002
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002